←Back to Expert Scholars
Translational Medicine / 转化医学AML Novel Targets, Menin Inhibitors
Eunice Wang
MD
🏢Roswell Park Comprehensive Cancer Center🌐USA
Chief, Leukemia Service
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Eunice Wang leads the leukemia service at Roswell Park and has been principal investigator of the revumenib trials that led to approval of the first menin inhibitor for KMT2A-rearranged leukemia. She has advanced therapy for NPM1-mutant AML with menin inhibition. Her work opens a new class of AML targeted therapy.
Share:
🧪Research Fields 研究领域
menin inhibitors
revumenib
KMT2A-rearranged AML
NPM1 AML
novel AML targets
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Eunice Wang 的研究动态
Follow Eunice Wang's research updates
留下邮箱，当我们发布与 Eunice Wang（Roswell Park Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment